Optiscan sees financial green shoots with medical devices | The...

Optiscan sees financial green shoots with medical devices | The West Australian


Optiscan Imaging says its latest financial results are just the tip of the iceberg, confident a stronger staff presence in the lucrative United States health market will soon reap the rewards for its revolutionary medical devices.
The company says its interest in its “ViewnVivo” life sciences product is steadily growing since it established a business development team in the US last October. While Optiscan’s latest quarterly results this week revealed just $27,000 in customer receipts – understood to be from a major, but unnamed, medical institution for the ViewnVivo device – it is adamant it is just the start of a promising money story.

Dr Farah said the company was putting its 2024 focus on delivering on its hardware and software commitments through the launch of surgical and pathology devices and the completion of its cloud-based telepathology platform. It also planned to continue to strengthen its position in the US medtech ecosystem, with strategic partnerships and collaborations it believes will accelerate the pathway to market.


In concert with its many other ongoing research and product refinements, the company says its business development, sales and marketing mission continues to advance in the US, China and Europe, with a specific focus on Germany and Switzerland.